Quest for the right Drug

|
עמוד הבית / ספקטרצף 400 מ"ג / מידע מעלון לרופא

ספקטרצף 400 מ"ג SPECTRACEF 400 MG (CEFDITOREN AS PIVOXIL)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות מצופות פילם : FILM COATED TABLETS

Posology : מינונים

4.2 Posology and method of administration
The recommended dosage depends on the severity of the infection, the basal condition of the patient and the potential micro-organisms involved.
Posology
Adults and adolescents (over 12 years)
• Acute pharyngo-tonsillitis: 200 mg cefditoren every 12 hours for 10 days.

• Acute maxillary sinusitis: 200 mg cefditoren every 12 hours for 10 days.
• Acute exacerbations of chronic bronchitis: 200 mg cefditoren every 12 hours for 5 days.
• Community-acquired pneumonia:
- In mild cases: 200 mg cefditoren every 12 hours for 14 days.
- In moderate cases: 400 mg cefditoren every 12 hours for 14 days.
• Uncomplicated skin and skin structure infections: 200 mg cefditoren every 12 hours for 10 days.

Elderly
No dose adjustments are necessary for elderly patients, except in the case of severe renal and/or hepatic function impairment.
Renal insufficiency
No dose adjustment is necessary for patients with mild renal impairment. In patients with moderate renal insufficiency (creatinine clearance 30-50 ml/min), the total daily dose should not exceed 200 mg cefditoren every 12 hours. In patients with severe renal insufficiency (creatinine clearance < 30 ml/min), it is recommended a single dose of 200 mg cefditoren once a day. The recommended dose has not been determined in patients undergoing dialysis (see sections 4.4 Special Warnings and Special Precautions for Use and 5.2 Pharmacokinetic Properties).
Hepatic insufficiency
No dose adjustments are necessary for patients with mild hepatic insufficiency (Child-Pugh A) to moderate hepatic insufficiency (Child-Pugh B). In the case of severe insufficiency (Child-Pugh C), there are no data available that would allow a recommended dose to be established (see section 5.2 Pharmacokinetic Properties).
Paediatric population
Spectracef is not indicated for children and adolescents under 12 years old.


Method of administration
Tablets should be swallowed whole with a sufficient quantity of water. Tablets should be taken with meals.


שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

TARO INTERNATIONAL LTD, ISRAEL

רישום

166 37 36016 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

30.09.21 - עלון לרופא

עלון מידע לצרכן

30.09.21 - עלון לצרכן אנגלית 30.09.21 - עלון לצרכן עברית 30.09.21 - עלון לצרכן ערבית

לתרופה במאגר משרד הבריאות

ספקטרצף 400 מ"ג

קישורים נוספים

RxList WebMD Drugs.com